BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21194074)

  • 21. Recent advances in the discovery of small molecule therapies for HCV.
    Myles DC
    Curr Opin Drug Discov Devel; 2001 Jul; 4(4):411-6. PubMed ID: 11727306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.
    Watkins-Riedel T; Ferenci P; Steindl-Munda P; Gschwantler M; Mueller C; Woegerbauer M
    Clin Infect Dis; 2004 Dec; 39(12):1754-60. PubMed ID: 15578395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virology: fresh assault on hepatitis C.
    Rice CM
    Nature; 2003 Nov; 426(6963):129-31. PubMed ID: 14578912
    [No Abstract]   [Full Text] [Related]  

  • 24. Convert hepatitis C virus into a non-enveloped virus like hepatitis A, by targeting its envelope rather than the RNA.
    Helmy A
    Med Hypotheses; 2006; 66(4):847-50. PubMed ID: 16229965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current Guidelines for treatment of hepatitis C. The eradication of HCV as a goal].
    Sarrazin C; Zeuzem S
    Pharm Unserer Zeit; 2011 Jan; 40(1):52-9. PubMed ID: 21194083
    [No Abstract]   [Full Text] [Related]  

  • 26. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus (HCV) therapies special thematic issue: call for papers.
    Georg GI; Wang S
    J Med Chem; 2013 Jan; 56(2):387. PubMed ID: 23294104
    [No Abstract]   [Full Text] [Related]  

  • 28. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question?
    Shedlofsky SI
    Am J Gastroenterol; 2002 May; 97(5):1093-6. PubMed ID: 12014712
    [No Abstract]   [Full Text] [Related]  

  • 29. Hepatitis C viral kinetics: the past, present, and future.
    Chatterjee A; Smith PF; Perelson AS
    Clin Liver Dis; 2013 Feb; 17(1):13-26. PubMed ID: 23177280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New treatment options for chronic hepatitis C.
    van Soest H; van Hattum J
    Adv Exp Med Biol; 2003; 531():219-26. PubMed ID: 12916794
    [No Abstract]   [Full Text] [Related]  

  • 31. Novel interferons for treatment of hepatitis C virus.
    Clark V; Nelson DR
    Clin Liver Dis; 2009 Aug; 13(3):351-63. PubMed ID: 19628153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New antiviral therapies for hepatitis C.
    O'Leary J; Chung RT
    Taehan Kan Hakhoe Chi; 2003 Dec; 9(4):265-74. PubMed ID: 14695693
    [No Abstract]   [Full Text] [Related]  

  • 33. A mutational shift from domain III to II in the internal ribosome entry site of hepatitis C virus after interferon-ribavirin therapy.
    Ogata K; Kashiwagi T; Iwahashi J; Hara K; Honda H; Ide T; Kumashiro R; Kohara M; Sata M; Watanabe H; Hamada N
    Arch Virol; 2008; 153(8):1575-9. PubMed ID: 18592133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Approaches for the development of antiviral compounds: the case of hepatitis C virus.
    Schinazi RF; Coats SJ; Bassit LC; Lennerstrand J; Nettles JH; Hurwitz SJ
    Handb Exp Pharmacol; 2009; (189):25-51. PubMed ID: 19048196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical consequences of hepatitis C virus quasispecies for target-specific antivirals.
    Fanning LJ
    J Infect Dis; 2008 Sep; 198(6):797-9. PubMed ID: 18637751
    [No Abstract]   [Full Text] [Related]  

  • 36. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication.
    Clark JL; Mason JC; Hollecker L; Stuyver LJ; Tharnish PM; McBrayer TR; Otto MJ; Furman PA; Schinazi RF; Watanabe KA
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1712-5. PubMed ID: 16368235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Introduction to hepatitis C virus (HCV) therapies special thematic issue.
    Meanwell NA; Watkins WJ
    J Med Chem; 2014 Mar; 57(5):1625-6. PubMed ID: 24484173
    [No Abstract]   [Full Text] [Related]  

  • 40. New therapeutic prospects in HCV treatment.
    Almasio PL; Ingrassia D; Vergara B; Filosto S
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):775-9. PubMed ID: 19053890
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.